Literature DB >> 10676661

Basic fibroblast growth factor confers a less malignant phenotype in MDA-MB-231 human breast cancer cells.

R M Korah1, V Sysounthone, Y Golowa, R Wieder.   

Abstract

Basic fibroblast growth factor (FGF-2) expression is associated with a more differentiated phenotype, earlier stage of disease, and a better prognosis in breast cancer patients. To determine whether expression of FGF-2 can cause a less malignant phenotype, we engineered MDA-MB-231 cells, a highly dedifferentiated, invasive breast cancer cell line, to express different isoforms of FGF-2. Cells expressed either cytoplasmic, nuclear, or a combination of both FGF-2 isoforms. Western blots of 2 M NaCl washes and of conditioned medium demonstrated that these cells did not export FGF-2. Cells expressing FGF-2 had levels of fibroblast growth factor receptors equivalent with those of control cells. Transformation was assayed by anchorage-independent colony formation and tumor formation in athymic mice. All of the constructs expressing various FGF-2 isoforms had a 60-70% reduction in colony formation in soft agar, but only cells expressing the Mr 18,000 FGF-2 isoform formed fewer and smaller tumors in mice. To determine potential mechanisms responsible for a less malignant phenotype, experiments measuring invasion in Matrigel, the secretion of matrix metalloprotease activity and migration in a modified Boyden chamber and in a patch wound motility assay were carried out. Cells expressing the Mr 18,000 cytoplasmic FGF-2 moiety had a 45% decrease in invasion in Matrigel compared to vector-transfected controls. Cells expressing Mr 18,000 FGF-2 had an increase in Mr 97,000 and Mr 48,000 collagenase, demonstrating that the decreased invasive potential was not due to a down-regulation of gelatinolytic or caseinolytic matrix metalloproteinases. However, motility was decreased in both assays, primarily in cells expressing Mr 18,000 FGF-2, whereas exogenous recombinant human FGF-2 had no effect. These studies demonstrate for the first time that FGF-2 expression can cause a less malignant phenotype in breast cancer cells, possibly as a result of decreased motility and invasion.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10676661

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

1.  Heparan sulfate proteoglycans and human breast cancer epithelial cell tumorigenicity.

Authors:  Rachel K Okolicsanyi; Andre J van Wijnen; Simon M Cool; Gary S Stein; Lyn R Griffiths; Larisa M Haupt
Journal:  J Cell Biochem       Date:  2014-05       Impact factor: 4.429

Review 2.  High molecular weight FGF2: the biology of a nuclear growth factor.

Authors:  K Chlebova; V Bryja; P Dvorak; A Kozubik; W R Wilcox; P Krejci
Journal:  Cell Mol Life Sci       Date:  2009-01       Impact factor: 9.261

3.  Breast cancer stem-like cells are inhibited by a non-toxic aryl hydrocarbon receptor agonist.

Authors:  Gérald J Prud'homme; Yelena Glinka; Anna Toulina; Olga Ace; Venkateswaran Subramaniam; Serge Jothy
Journal:  PLoS One       Date:  2010-11-03       Impact factor: 3.240

4.  The RUNX1 transcription factor is expressed in serous epithelial ovarian carcinoma and contributes to cell proliferation, migration and invasion.

Authors:  Mamadou Keita; Magdalena Bachvarova; Chantale Morin; Marie Plante; Jean Gregoire; Marie-Claude Renaud; Alexandra Sebastianelli; Xuan Bich Trinh; Dimcho Bachvarov
Journal:  Cell Cycle       Date:  2013-02-26       Impact factor: 4.534

Review 5.  Molecular pathology of the fibroblast growth factor family.

Authors:  Pavel Krejci; Jirina Prochazkova; Vitezslav Bryja; Alois Kozubik; William R Wilcox
Journal:  Hum Mutat       Date:  2009-09       Impact factor: 4.878

6.  Axl activates fibroblast growth factor receptor pathway to potentiate survival signals in B-cell chronic lymphocytic leukemia cells.

Authors:  S Sinha; J Boysen; M Nelson; S L Warner; D Bearss; N E Kay; A K Ghosh
Journal:  Leukemia       Date:  2015-11-24       Impact factor: 11.528

7.  Overexpression of vascular endothelial growth factor 189 in breast cancer cells leads to delayed tumor uptake with dilated intratumoral vessels.

Authors:  Marie-Astrid Hervé; Hélène Buteau-Lozano; Roger Vassy; Ivan Bieche; Guillaume Velasco; Marika Pla; Gérard Perret; Samia Mourah; Martine Perrot-Applanat
Journal:  Am J Pathol       Date:  2007-12-13       Impact factor: 4.307

8.  The interplay between hypoxia, endothelial and melanoma cells regulates vascularization and cell motility through endothelin-1 and vascular endothelial growth factor.

Authors:  Francesca Spinella; Valentina Caprara; Roberta Cianfrocca; Laura Rosanò; Valeriana Di Castro; Emirena Garrafa; Pier Giorgio Natali; Anna Bagnato
Journal:  Carcinogenesis       Date:  2014-01-28       Impact factor: 4.944

Review 9.  The role of fibroblast growth factors in tumor growth.

Authors:  M Korc; R E Friesel
Journal:  Curr Cancer Drug Targets       Date:  2009-08-01       Impact factor: 3.428

10.  Dual FGF-2 and intergrin alpha5beta1 signaling mediate GRAF-induced RhoA inactivation in a model of breast cancer dormancy.

Authors:  Judith Barrios; Robert Wieder
Journal:  Cancer Microenviron       Date:  2009-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.